S. Nasim, P. A. Crooks / Tetrahedron Letters 50 (2009) 257–259
259
Table 1
2. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F. J. J. Med. Chem. 2002,
45, 1292–1299.
Scope of NCS-induced TDZDs formation
3. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I.; Gelpi, J. L.; Luque, F. J.; Perez,
C.; Moreno, F. J. J. Med. Chem. 2005, 48, 7103–7112.
4. Martinez, A.; Castro, A.; Dorronsoro, I.; Mercedes, A. Med. Res. Rev. 2002, 22,
373–384.
5. Guzman, M. L.; Xiaojie, L.; Corbett, C. A.; Rossi, R. M.; Bushnell, T.; Liesveld, J. L.;
Hebert, J.; Young, F.; Jordan, C. T. Blood 2007, 110, 4436–4444.
6. Slomczynska, U.; Barany, G. J. Heterocycl. Chem. 1984, 21, 241–246.
7. Pilgram, K. H.; Gale, L. H. J. Heterocycl. Chem. 1988, 25, 607–613.
8. Ottmann, G. F.; Hooks, H. Angew. Chem. 1965, 77, 427.
O
O
O
N
S
N
R1 NCS
Cl
N R1
CHCl3, rt, 12 h
R2
R2 NCO
O
1
No
R1
R2
Equiv. of NCS
Yield (%)
9. Hussein, A. Q.; Jochims, J. C. Chem. Ber. 1979, 112, 1948–1955.
10. Patnaik, P. Handbook of Inorganic Chemicals; McGraw-Hill: New York, 2003. p
687.
11. Ishizaki, M.; Yamada, M.; Watanabe, S.; Hoshino, O.; Nishitani, K.; Hayashida,
M.; Tanaka, A.; Hara, H. Tetrahedron 2004, 60, 7973–7981.
1
2
Bn
Bn
Hexyl
Bn
Et
Bn
Bn
2-Cl–Et
Et
4
4
4
4
4
4
4
4
45
50
52
39
45
40
34
52
313
414
5
Ph
12. General experimental procedure: The appropriate isothiocyanate (1 mmol)
and isocyanate (1 mmol) were each dissolved in anhydrous CHCl3
(10 mL/mmol) and NCS (4 mmol) was added in one portion. After stirring at
rt for 12 h under argon and subsequently for 10 min in air, the reaction mixture
was diluted with diethylether and filtered through a sintered glass funnel to
remove unreacted NCS and the precipitated succinimide. The filtrate was
concentrated under reduced pressure and subjected to column
chromatography over silica gel, eluted with 15–20% diethylether–hexanes to
isolate the pure product.
6
7
8
Cyclohexyl
Bn
Bn
Et
Allyl
2-(Carboxyethyl)-ethyl
O
O
9
Bn
4
50
13. 2-Benzyl-4-hexyl-1,2,4-thiadiazolidine-3,5-dione: yellow oil; yield: 52%. 1H NMR
(300 MHz, CDCl3) d 7.34–7.26 (m, 5H), 4.75 (s, 2H), 3.67 (t, J = 7.5 Hz, 2H), 1.66
(m, 2H), 1.30 (m, 6H), 0.87 (t, J = 5.7 Hz, 3H). 13C NMR (300 MHz, CDCl3) d
166.0, 153.4, 134.8, 129.1, 128.9, 128.6, 48.8, 43.1, 31.6, 28.1, 26.6, 22.8, 14.3.
GC–MS m/z 292. Anal. (C15H20N2O2S) C, H, N.
10
1115
m-Anisyl
Bn
Allyl
Ph
4
3–10
21
10
Acknowledgment
14. 2-Chloroethyl-benzyl-1,2,4-thiadiazolidine-3,5-dione: clear viscous oil; yield:
39%. 1H NMR (300 MHz, CDCl3) d 7.44–7.32 (m, 5H), 4.83 (s, 2H), 3.92 (t,
J = 5.7 Hz, 2H), 3.69 (t, J = 5.7 Hz, 2H); 13C NMR (300 MHz, CDCl3) d 165.8,
153.2, 135.0, 128.9, 128.8, 128.4, 46.9, 46.2, 42.1. GC–MS m/z 270. Anal.
(C11H11ClN2O2S) C, H, N.
Financial support from the Leukemia-Lymphoma Society, Grant
#6077-08, is gratefully acknowledged.
15. 2-Phenyl-4-benzyl-1,2,4-thiadiazolidine-3,5-dione: white solid; mp 90 °C; yield:
10%. 1H NMR (300 MHz, CDCl3) d 7.53–7.25 (m, 10H), 4.91 (s, 2H). 13C NMR
(300 MHz, CDCl3) d 165.1, 151.1, 135.9, 135.1, 129.6, 129.3, 128.9, 128.6, 127.1,
123.5, 46.4. GC–MS m/z 284. Anal. (C15H12N2O2S) C, H, N.
References and notes
1. Martinez, A.; Fernandez, E.; Castro, A.; Conde, S.; Rodriguez-Franco, I.; Banos,
J-E.; Badia, A. Eur. J. Med. Chem. 2000, 35, 913–922.